Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096221123144
Abstract: Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis.… read more here.
Keywords: recurrent vulvovaginal; candidiasis ibrexafungerp; treatment recurrent; candidiasis ... See more keywords